source
- RevMed’s experimental pancreatic cancer drug available via expanded access as FDA voucher program faces potential changesRevMed's experimental pancreatic cancer therapy daraxonrasib has not received FDA approval yet, but the company is offering it through an expanded access (compassionate use) program. Access to the…
- Texas attorney general probes energy drink safety as federal research ethics office shrinks dramaticallyThe Texas attorney general has opened an inquiry into the safety and marketing claims of popular energy drinks, seeking to determine whether they pose health risks or violate state consumer protect…